Ipsen news

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 10 News

Show

Sort

22 September 2025

22 September 2025

U.K. MHRA grants marketing authorisation for Cabozantinib Ipsen®– a first for previously treated advanced neuroendocrine tumours

07 April 2025

07 April 2025

The Scottish Medicines Consortium (SMC) accepts Ipsen’s IQIRVO® (elafibranor) for use in NHS Scotland – the first new medicine in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease

22 October 2024

22 October 2024

NICE recommends Ipsen’s IQIRVO® (elafibranor) – the first medicine approved for NHS use in nearly a decade for primary biliary cholangitis (PBC), a rare liver disease

08 October 2024

08 October 2024

U.K. MHRA grants marketing authorisation for Ipsen’s Iqirvo® (elafibranor), a first-in-class peroxisome proliferator-activated receptor (PPAR) treatment for primary biliary cholangitis (PBC)

07 March 2024

07 March 2024

Ipsen appoints Ioana Parsons as General Manager, U.K. & Ireland

CRSC-GB-000393

January 2026